The U.S. dollar extended its recent weakness on Wednesday, as risk sentiment improved after Gilead Sciences claimed that the results of its study showed improvement in patients taking its remdesivir to treat the coronavirus infection.
The National Institute of Allergy and Infectious Diseases has said that a study of Gilead's remdesivir drug met its primary endpoint, lifting expectations for a potential coronavirus treatment.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com